Your browser doesn't support javascript.
loading
Radiotheranostics in advanced prostate cancer: Current and future directions.
Jia, Angela Y; Kiess, Ana P; Li, Qiubai; Antonarakis, Emmanuel S.
Afiliação
  • Jia AY; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Angela.Jia@UHhospitals.org.
  • Kiess AP; Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD, USA.
  • Li Q; Department of Nuclear Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
  • Antonarakis ES; University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
Prostate Cancer Prostatic Dis ; 27(1): 11-21, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37069330
ABSTRACT
The discovery of small molecules that target the extracellular domain of prostate-specific membrane antigen (PSMA) has led to advancements in diagnostic imaging and the development of precision radiopharmaceutical therapies. In this review, we present the available existing data and highlight the key ongoing clinical evaluations of PSMA-based imaging in the management of primary, biochemically recurrent, and metastatic prostate cancer. We also discuss clinical studies that explore the use of PSMA-based radiopharmaceutical therapy (RPT) in metastatic prostate cancer and forthcoming trials that investigate PSMA RPT in earlier disease states. Multidisciplinary collaboration in clinical trial design and therapeutic administration is critical to the continued progress of this evolving radiotheranostics field.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Idioma: En Ano de publicação: 2024 Tipo de documento: Article